Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neuronetics attracts Christopher Thatcher as CEO

This article was originally published in Clinica

Executive Summary

Neuronetics, which specializes in transcranial magnetic stimulation (TMS) for depression, has made Christopher Thatcher president and CEO. Mr Thatcher was most recently divisional vice-president and business unit manager of the Reichert Technology Global Business Unit of Ametek, where he was responsible for revitalizing the brand and expanding the business globally. Prior to this, he was president of Integra Life Sciences’ neurosurgery division and corporate initiatives; vice-president cataract and vitreoretinal surgery at Bausch + Lomb; and held senior sales and marketing roles at Allergan. Neuronetics’ flagship NeuroStar TMS device received US FDA 510(k) clearance in 2008 for drug-resistant depression. Mr Thatcher replaces Bruce Shook, who in July left Neuronetics after 11 years to become president and CEO of Intact Vascular.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT102178

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel